摘要
目的通过研究新辅助化疗对乳腺癌根治术后病理诊断的影响,评价新辅助化疗的临床价值。方法对100例经空芯针穿刺取材病理确诊的乳腺癌患者,给予临床证实有效的新辅助化疗方案2周期治疗,继之行根治术,术后病理检查并做免疫组化测ER、PR和c-erbB-2,与化疗前的检查结果比对,进行总结。结果经新辅助化疗后,乳腺癌原发灶明显缩小,11%完全缓解;腋窝淋巴结阳性率下降,21.6%完全缓解;ER、PR和c-erbB-2结果与新辅助化疗前不相符,不符合率分别为46%、37%和12%。结论新辅助化疗对降低病期、争取保乳机会、筛选敏感的化疗药物大有益处,但因其影响了术后病理结果,不利于医生制定放疗、内分泌治疗及基因治疗等方案,有待于进一步研究解决此矛盾。
ObjectiveTo evaluate the clinical value of neo-adjuvant chemotherapy for breast cancer by studying the effect of neo-adjuvant chemotherapy on pathological stage. Methods 100 breast cancer patients had been pathologically confirmed and received radical operation after 2 cycles of neoadjuvant chemotherapy, The pathological results before and after therapy were compared and analyzed. Results After neo-adjuvant chemotherapy, the primary cancer became smaller, 11% of which was completely release（CR） ; the rate of positive axillary lymph node decreasd, 21.6% was completely release（CR） ; ER （46 % ）, PR （37 % ） and c- erbB-2 （ 12 % ） were quite different from those before therapy. Conclusion Neo-adjuvant chemotherapy may be good for decreasing the clinical stage, earning chance for breast conservation operation and screening sensitive drugs for breast cancer, but it also causes effect on postoperation pathological results. That is no good for doctors to make therapy plan.
出处
《实用临床医药杂志》
CAS
2005年第7期41-42,共2页
Journal of Clinical Medicine in Practice
关键词
乳腺癌
新辅助化疗
病理
breast cancer
neo-adjuvant chemotherapy
pathology
